Storia in 4 fonti

AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave

Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s camizestrant PDUFA date; and more

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 mesi fa

AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave

Kailera touts early weight loss data; Arrowhead takes a shot at the same obesity target as Wave; FDA delays AstraZeneca’s camizestrant PDUFA date; and more

originale

Timeline cronologica

mercoledì 27 maggio 2026·biopharmadive.com
FDA delays decision on AstraZeneca breast cancer pill
The review extension comes weeks after an advisory panel found the evidence supporting the drug, camizestrant, inconclusive in what would be a new kind of treatment setting.
mercoledì 27 maggio 2026·independent.co.uk
AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data
This extension follows an April vote by a majority of the FDA's advisory panel against the drug when used in combination with a CDK4/6 inhibitor

AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave

Confronto fonti

AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave

Timeline cronologica

FDA delays decision on AstraZeneca breast cancer pill

AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

AstraZeneca’s ‘game changer’ cancer pill stuck in limbo as FDA demands more data

FDA delays decision on AstraZeneca breast cancer pill

AstraZeneca breast cancer pill faces review delay from regulators

FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote

AstraZeneca's breast cancer PDUFA delayed; Arrowhead aims at same obesity target as Wave